ReviewOrphanet journal of rare diseases2024

Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.

Catherine Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.